OncoMatch/Clinical Trials/NCT07226427

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

Is NCT07226427 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies MEN2501 for platinum-resistant ovarian cancer.

Phase 1RecruitingStemline Therapeutics, Inc.NCT07226427Data as of May 2026

Treatment: MEN2501 — This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

NEXT Virginia · Fairfax, Virginia

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify